The excitement for $NVLX - and its investors is th
Post# of 63696
Posted On: 03/04/2014 9:21:24 AM
The excitement for $NVLX - and its investors is that, in those two completed Phase II trials, the treatment that Nuvilex owns the rights to use outperformed Eli Lilly's long-time single-agent treatment for advanced inoperable pancreatic cancer, Gemzar® (gemcitabine), and Celgene's recently approved drug Abraxane (a nanoparticle formulation of the widely used drug Taxol with albumin) in combination with gemcitabine http://www.stockwatch.com/News/Item.aspx?bid=...p;region=U
(0)
(0)Scroll down for more posts ▼